极高危原发性轻链型淀粉样变患者的临床特征和预后分析
目的探讨极高危原发性轻链型淀粉样变（pAL）患者的临床特征及其预后。方法回顾性分析2009年1月至2016年2月在北京协和医院确诊的205例pAL患者的临床资料，将梅奥2004分期111b期或梅奥2012分期4期的患者定义为极高危患者。结果34例（16．6％）为极高危pAL患者，中位年龄57（20～84）岁，男性22例（64．7％）。所有患者均有心脏受累，15例（44．1％）患者的受累脏器≥3个。27例（81．8％）患者的心功能分级为3-4级，中位血清肌钙蛋白I为0．25（0．08-1．23）μg／L，中位血清N末端B型利钠肽前体为11733（1892～103277）ng／L，中位血清游离轻链...
Saved in:
| Published in | 中华血液学杂志 Vol. 38; no. 2; pp. 107 - 111 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
100730,中国医学科学院、北京协和医学院北京协和医院血液内科%100730,中国医学科学院、北京协和医学院北京协和医院病理科%100730,中国医学科学院、北京协和医学院北京协和医院心内科
2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-2727 |
| DOI | 10.3760/cma.j.issn.0253-2727.2017.02.005 |
Cover
Loading…
| Abstract | 目的探讨极高危原发性轻链型淀粉样变（pAL）患者的临床特征及其预后。方法回顾性分析2009年1月至2016年2月在北京协和医院确诊的205例pAL患者的临床资料，将梅奥2004分期111b期或梅奥2012分期4期的患者定义为极高危患者。结果34例（16．6％）为极高危pAL患者，中位年龄57（20～84）岁，男性22例（64．7％）。所有患者均有心脏受累，15例（44．1％）患者的受累脏器≥3个。27例（81．8％）患者的心功能分级为3-4级，中位血清肌钙蛋白I为0．25（0．08-1．23）μg／L，中位血清N末端B型利钠肽前体为11733（1892～103277）ng／L，中位血清游离轻链差值为403．0（18．1～1911．6）mg／L，8例（24．2％）患者的骨髓浆细胞比例I〉0．100。16例（47．1％）患者采用硼替佐米为主的化疗方案，总体血液学缓解率为58.3％。中位随诊27（1-40）个月，14例（41．2％）患者在诊断后3个月内死亡，中位生存时间仅为4个月。3、6、12和24个月的预期生存率分别为51．3％、44．0％、35．2％和29．6％。一线化疗后获得血液学缓解、未获得血液学缓解以及姑息治疗的患者1年预计存活率分别为90．9％、11．1％及0（P〈0．001）。结论极高危pAL患者的预后极差，早期病死率高，获得血液学缓解的pAL患者有着明显更好的预后。 |
|---|---|
| AbstractList | 目的 探讨极高危原发性轻链型淀粉样变(pAL)患者的临床特征及其预后.方法 回顾性分析2009年1月至2016年2月在北京协和医院确诊的205例pAL患者的临床资料,将梅奥2004分期Ⅲb期或梅奥2012分期4期的患者定义为极高危患者.结果 34例(16.6％)为极高危pAL患者,中位年龄57(20～84)岁,男性22例(64.7％).所有患者均有心脏受累,15例(44.1％)患者的受累脏器≥3个.27例(81.8％)患者的心功能分级为3～4级,中位血清肌钙蛋白I为0.25(0.08～1.23) μg/L,中位血清N末端B型利钠肽前体为11 733(1 892～103 277) ng/L,中位血清游离轻链差值为403.0(18.1～1 911.6) mg/L,8例(24.2％)患者的骨髓浆细胞比例≥0.100.16例(47.1％)患者采用硼替佐米为主的化疗方案,总体血液学缓解率为58.3％.中位随诊27(1～40)个月,14例(41.2％)患者在诊断后3个月内死亡,中位生存时间仅为4个月.3、6、12和24个月的预期生存率分别为51.3％、44.0％、35.2％和29.6％.一线化疗后获得血液学缓解、未获得血液学缓解以及姑息治疗的患者1年预计存活率分别为90.9％、11.1％及0(P＜0.001).结论 极高危pAL患者的预后极差,早期病死率高,获得血液学缓解的pAL患者有着明显更好的预后. 目的探讨极高危原发性轻链型淀粉样变（pAL）患者的临床特征及其预后。方法回顾性分析2009年1月至2016年2月在北京协和医院确诊的205例pAL患者的临床资料，将梅奥2004分期111b期或梅奥2012分期4期的患者定义为极高危患者。结果34例（16．6％）为极高危pAL患者，中位年龄57（20～84）岁，男性22例（64．7％）。所有患者均有心脏受累，15例（44．1％）患者的受累脏器≥3个。27例（81．8％）患者的心功能分级为3-4级，中位血清肌钙蛋白I为0．25（0．08-1．23）μg／L，中位血清N末端B型利钠肽前体为11733（1892～103277）ng／L，中位血清游离轻链差值为403．0（18．1～1911．6）mg／L，8例（24．2％）患者的骨髓浆细胞比例I〉0．100。16例（47．1％）患者采用硼替佐米为主的化疗方案，总体血液学缓解率为58.3％。中位随诊27（1-40）个月，14例（41．2％）患者在诊断后3个月内死亡，中位生存时间仅为4个月。3、6、12和24个月的预期生存率分别为51．3％、44．0％、35．2％和29．6％。一线化疗后获得血液学缓解、未获得血液学缓解以及姑息治疗的患者1年预计存活率分别为90．9％、11．1％及0（P〈0．001）。结论极高危pAL患者的预后极差，早期病死率高，获得血液学缓解的pAL患者有着明显更好的预后。 |
| Abstract_FL | Objective To evaluate the clinical characteristics and outcomes of very high risk patients with primary immunoglobulin light-chain amyloidosis (pAL) at a single center in China.Method Clinical data,treatment and outcome of 205 pAL patients in Peking Union Medical College Hospital from January 2009 to February 2016 were retrospectively analyzed.A ‘very high risk’ group includes patients with Mayo 2004 stage Ⅲb and Mayo 2012 stage 4.Results Of 205 patients,34 (16.6％) were defined as very high risk pAL patients.The median age at diagnosis was 57 (20-84) years,and 22 patients (64.7％) were male.All 34 patients were diagnosed with cardiac involvement,multi-organ involvement was observed in 15 patients (44.1％),and 27(81.8％) had New York Heart Association Class Ⅲ or Ⅳ.Median values of serum cTnI,NT-proBNP,and free light chains difference were 0.25 μg/L,11 733 ng/L,and 403 mg/L,respectively.Eight (24.2％) had more than 10％ plasma cell on the bone marrow aspirate.Sixteen (47.1％) patients received bortezomib based chemotherapy and overall hematologic response rate was 58.3％.Median overall survival (OS) was 4 months.The estimated OS at 3,6,12,and 24 months was 51.3％,44.0％,35.2％,and 29.6％,respectively.Fourteen (41.2％) patients died within 3 months after the diagnosis.The estimated 1-year survival rate for the patients who got hematologic response,without hematologic response,and palliative treatment was 90.9％,11.1％,and 0,respectively (P＜0.001).Conclusion Patients with very high risk pAL had very poor prognosis and the early death rate remained high.Those patients who obtained hematologic remission would have significantly better outcomes. |
| Author | 冯俊 黄栩芾 张聪丽 沈恺妮 张春兰 孙健 田庄 曹欣欣 张路 周道斌 李剑 |
| AuthorAffiliation | 中国医学科学院、北京协和医学院北京协和医院血液内科,100730 中国医学科学院、北京协和医学院北京协和医院病理科,100730 中国医学科学院、北京协和医学院北京协和医院心内科,100730 |
| AuthorAffiliation_xml | – name: 100730,中国医学科学院、北京协和医学院北京协和医院血液内科%100730,中国医学科学院、北京协和医学院北京协和医院病理科%100730,中国医学科学院、北京协和医学院北京协和医院心内科 |
| Author_xml | – sequence: 1 fullname: 冯俊 黄栩芾 张聪丽 沈恺妮 张春兰 孙健 田庄 曹欣欣 张路 周道斌 李剑 |
| BookMark | eNo9j0tPwkAUhWeBiYD-CRfGTevttNPpLA3xFUncsCdtaXlEBqUxgiswYMQHoG6ICzS6cOFKY4KPyK9xCvwLx2Bc3dx7vtxzTgxFeIl7CC1poOrUhGW3aKsFNR8EXAVMdAVTTFUMGpWrCkAiKPp_n0WxICgAGFI3omgr7NcnTz1x8Szat6JzGdYex1-fk-uh6J-Fg9ropRXeDUSnFx49jGvN0U3j--1VfJyOWu9iWBdX55P7hui2xclx2O_OoRnf3gm8-b8ZR6m11VRiQ0lur28mVpKKSyyiEJJxADsUHJeYludRz2eY-Uz3sEeJDO3bGcshzMCmpbs2dgyTgslAy2jMYtjQ42hx-vbA5r7Ns-lCab_MpWH6MFepVn57A5atJbgwBd1ciWf38hLdLeeLdrmaNqmGNdCJqf8AVJJ3zQ |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3760/cma.j.issn.0253-2727.2017.02.005 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Analysis of clinical characteristics and outcome immunoglobulin light- chain amyloidosis |
| DocumentTitle_FL | Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis |
| EndPage | 111 |
| ExternalDocumentID | zhxyx201702005 671210356 |
| GroupedDBID | --- -05 2B. 2C~ 2RA 92F 92I 92L ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 F5P OK1 RPM TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI PSX |
| ID | FETCH-LOGICAL-c585-55db02b70bc568ee7ef929f93e2e75017fad8b5942683ca2b46706901d1989243 |
| ISSN | 0253-2727 |
| IngestDate | Thu May 29 04:00:17 EDT 2025 Wed Feb 14 10:18:50 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Very high risk Bortezomib Primary light chain amyloidosis 极高危 硼替佐米 原发性轻链型淀粉样变 |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c585-55db02b70bc568ee7ef929f93e2e75017fad8b5942683ca2b46706901d1989243 |
| Notes | Feng Jun, of patients with very high risk primary Huang Xufei, Zhang Congli, Shen Kaini, Zhang Chunlan, Sun Jian, Tian Zhuang, Cao Xinxin, Zhang Lu, Zhou Daobin, Li Jian（Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beo＇ing 100730, China） 12-1090/R Primary light chain amyloidosis; Very high risk; Bortezomib Objective To evaluate the clinical characteristics and outcomes of very high risk patients with primary immunoglobulin light-chain amyloidosis （pAL） at a single center in China. Method Clinical data, treatment and outcome of 205 pAL patients in Peking Union Medical College Hospital from January 2009 to February 2016 were retrospectively analyzed. A ＇very high risk＇ group includes patients with Mayo 2004 stage II1 b and Mayo 2012 stage 4. Results Of 205 patients, 34 （16.6%） were defined as very high risk pAL patients. The median age at diagnosis was 57 （20 - 84） years, and 22 patients （64.7%） were male. All 34 patients were diagnosed with cardiac involvem |
| PageCount | 5 |
| ParticipantIDs | wanfang_journals_zhxyx201702005 chongqing_primary_671210356 |
| PublicationCentury | 2000 |
| PublicationDate | 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017 |
| PublicationDecade | 2010 |
| PublicationTitle | 中华血液学杂志 |
| PublicationTitleAlternate | Chinese Journal of Hematology |
| PublicationTitle_FL | Chinese Journal of Hematology |
| PublicationYear | 2017 |
| Publisher | 100730,中国医学科学院、北京协和医学院北京协和医院血液内科%100730,中国医学科学院、北京协和医学院北京协和医院病理科%100730,中国医学科学院、北京协和医学院北京协和医院心内科 |
| Publisher_xml | – name: 100730,中国医学科学院、北京协和医学院北京协和医院血液内科%100730,中国医学科学院、北京协和医学院北京协和医院病理科%100730,中国医学科学院、北京协和医学院北京协和医院心内科 |
| SSID | ssj0042014 ssib051368330 ssib017477332 ssib001103535 ssib058574913 |
| Score | 2.0939245 |
| Snippet | ... 目的 探讨极高危原发性轻链型淀粉样变(pAL)患者的临床特征及其预后.方法 回顾性分析2009年1月至2016年2月在北京协和医院确诊的205例pAL患者的临床资料,将梅奥2004分期Ⅲb期或梅奥2012分期4期的患者定义为极高危患者.结果... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 107 |
| SubjectTerms | 原发性轻链型淀粉样变 极高危 硼替佐米 |
| Title | 极高危原发性轻链型淀粉样变患者的临床特征和预后分析 |
| URI | http://lib.cqvip.com/qk/93752X/201702/671210356.html https://d.wanfangdata.com.cn/periodical/zhxyx201702005 |
| Volume | 38 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw3V1Lb9QwEI6qVkJcEAgQpTx6wBKXlCSOE_vo7GZVgeBUpN5WSTbbCoktj1YqPbWoIMqjLXCpOBQEBw6cQEjlIfpryLaV-BHMON5s-pBKOfay8trjz9_M5DFj2Y5hXBJeUyTUt0wGuZfpQgxgRhbjkKqkkK3QlDcs3Jx8_YY3fNO9OspGe_r-lFYtTU3GQ8nMnvtK_serUAd-xV2yB_BsAQoVUAb_wi94GH7_ycck9IgIIRgkoSAyIIKTkBFeJYGtCiERNVWoEWGjMLeI9EnISQAyAfYSlAQhyiBOgDKBj2KhTwKHcIE10sJKjcMVjkMkRRyQ5AyFhSTcJaFLAgB3UTiAGolNABIIVZNThbEAuaI4O6oX1FjIFocATE_rlX_hsxM6a3BZ1TqiPPy1FVug7SFhaAIBmSNUkSeOC7SL163qDTrVFF4NOHZbBBoFCSmdpVAaSuBd7hxUsBFbbCJlR-VqV0QR4bmdbDQDkgLEsDzDkm8lVXcDriChFlzr2zQUAToJyVaUqwrFfHShsEs14EVlypAqf9i6l_AVoCSy0jFZrWT93cgFzoG6F732cgZYOr8-cs4Q5h4SZX3soi99S12yh09HdedwutuPpejBYdR0_PzgjU6oQ3npke6U4hb96WkdAuv4Z2d0hevn4JGY3I6GbqlBhopBcI2snx9-zLqRZbHed2Z8-sE0ilj5gdN9DiT11o65VUhEKOsmb8ymHqfdyQ3Gme-qNRV5nO0CnjocsMPhiHFZk7yyH0U8SGd8ojV2F9IDtVuz1YxaY6XEYuS4cUzPCAzK_PF-wuiZGT9pXGuvzm19WslefM4W32ZLL9uzHzd__dx6vZ6tPmuvzW58WWi_W8uWVtoPP2zOPtp4M__729fsx9ONhe_Z-lz26vnW-_lseTF78ri9unzKGKmFI5VhU3_3xkxASZOxRmw5sW_FCfN4mvppE3LYpqCpk0J-Z_vNqMFjJiC34jSJnBhiXTxv3m7g-lfHpaeN3tZEKz1jDMZNr8GTBJJEytwIwrdYcC_yXNtuOimlab8xUNihfic_3qju-XioJGVev3FRW6auX3r369s9eXZfiQHjKJbzSetzRu_kvan0PKRxk_EF5f2_iyUhJQ |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%9E%81%E9%AB%98%E5%8D%B1%E5%8E%9F%E5%8F%91%E6%80%A7%E8%BD%BB%E9%93%BE%E5%9E%8B%E6%B7%80%E7%B2%89%E6%A0%B7%E5%8F%98%E6%82%A3%E8%80%85%E7%9A%84%E4%B8%B4%E5%BA%8A%E7%89%B9%E5%BE%81%E5%92%8C%E9%A2%84%E5%90%8E%E5%88%86%E6%9E%90&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E5%86%AF%E4%BF%8A&rft.au=%E9%BB%84%E6%A0%A9%E8%8A%BE&rft.au=%E5%BC%A0%E8%81%AA%E4%B8%BD&rft.au=%E6%B2%88%E6%81%BA%E5%A6%AE&rft.date=2017&rft.pub=100730%2C%E4%B8%AD%E5%9B%BD%E5%8C%BB%E5%AD%A6%E7%A7%91%E5%AD%A6%E9%99%A2%E3%80%81%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E5%AD%A6%E9%99%A2%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E9%99%A2%E8%A1%80%E6%B6%B2%E5%86%85%E7%A7%91%25100730%2C%E4%B8%AD%E5%9B%BD%E5%8C%BB%E5%AD%A6%E7%A7%91%E5%AD%A6%E9%99%A2%E3%80%81%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E5%AD%A6%E9%99%A2%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E9%99%A2%E7%97%85%E7%90%86%E7%A7%91%25100730%2C%E4%B8%AD%E5%9B%BD%E5%8C%BB%E5%AD%A6%E7%A7%91%E5%AD%A6%E9%99%A2%E3%80%81%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E5%AD%A6%E9%99%A2%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E9%99%A2%E5%BF%83%E5%86%85%E7%A7%91&rft.issn=0253-2727&rft.volume=38&rft.issue=2&rft.spage=107&rft.epage=111&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-2727.2017.02.005&rft.externalDocID=zhxyx201702005 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93752X%2F93752X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg |